



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Jürgen Hubbuch,
✉ juergen.hubbuch@kit.edu

RECEIVED 26 May 2023
ACCEPTED 31 May 2023
PUBLISHED 09 June 2023

CITATION
Weggen JT, Seidel J, Bean R, Wendeler M
and Hubbuch J (2023), Corrigendum:
Kinetic studies and CFD-based reaction
modeling for insights into the scalability
of ADC conjugation reactions.
Front. Bioeng. Biotechnol. 11:1229416.
doi: 10.3389/fbioe.2023.1229416

COPYRIGHT
© 2023 Weggen, Seidel, Bean, Wendeler
and Hubbuch. This is an open-access
article distributed under the terms of the
[Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is
permitted, provided the original author(s)
and the copyright owner(s) are credited
and that the original publication in this
journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: Kinetic studies and CFD-based reaction modeling for insights into the scalability of ADC conjugation reactions

Jan Tobias Weggen¹, Janik Seidel¹, Ryan Bean²,
Michaela Wendeler² and Jürgen Hubbuch^{1*}

¹Institute of Process Engineering in Life Sciences, Section IV: Biomolecular Separation Engineering, Karlsruhe Institute of Technology (KIT), Karlsruhe, Germany, ²Purification Process Sciences, BioPharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, MD, United States

KEYWORDS

antibody-drug conjugate (ADC), conjugation reaction, computational fluid dynamics (CFD), mixing, scale-up, single-use, kinetic modeling

A Corrigendum on

Kinetic studies and CFD-based reaction modeling for insights into the scalability of ADC conjugation reactions

by Weggen JT, Seidel J, Bean R, Wendeler M and Hubbuch J (2023). *Front. Bioeng. Biotechnol.* 11:1123842. doi: 10.3389/fbioe.2023.1123842

In the published article, there was an error in **Affiliation** [2]. Instead of “Purification Process Sciences, BioPharmaceuticals Development, Gaithersburg, MD, United States” it should be “Purification Process Sciences, BioPharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, MD, United States”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Conflict of interest

Authors MW and RB are employed by AstraZeneca PLC.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.